Somewhat Favorable News Coverage Somewhat Unlikely to Affect Edwards Lifesciences (EW) Stock Price
Media coverage about Edwards Lifesciences (NYSE:EW) has trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.7442208897752 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Commit To Purchase Edwards Lifesciences Corp At $123, Earn 45.1% Annualized Using Options – Nasdaq (nasdaq.com)
- Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings (finance.yahoo.com)
- Edwards Lifesciences’ (EW) THVT Likely to Drive Q4 Earnings (zacks.com)
- [$$] Biomedical Startup Investor Epidarex Capital Plans Expansion (finance.yahoo.com)
- Comparing Edwards Lifesciences (EW) & IRIDEX (IRIX) (americanbankingnews.com)
Edwards Lifesciences (NYSE:EW) traded up $0.60 during midday trading on Monday, reaching $124.51. 1,116,123 shares of the company’s stock traded hands, compared to its average volume of 1,226,271. Edwards Lifesciences has a fifty-two week low of $86.55 and a fifty-two week high of $124.57. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The stock has a market cap of $26,270.00, a PE ratio of 36.19, a PEG ratio of 1.98 and a beta of 0.51.
Edwards Lifesciences announced that its board has initiated a stock buyback program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
EW has been the subject of a number of research reports. Cowen set a $135.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Sunday, December 10th. BMO Capital Markets restated a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 8th. Canaccord Genuity restated a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. SunTrust Banks set a $124.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Barclays dropped their price target on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 25th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $129.57.
In other Edwards Lifesciences news, VP Larry L. Wood sold 6,300 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total value of $762,300.00. Following the sale, the vice president now directly owns 116,148 shares in the company, valued at approximately $14,053,908. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The disclosure for this sale can be found here. Insiders sold a total of 197,820 shares of company stock worth $21,760,908 over the last quarter. Corporate insiders own 2.13% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.